CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

Company Overview

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.

Key Stats

• Today's Range: $0.0064 to $0.0069
• 50-Day Range: $0.0060 to $0.0138
• 52-Week Range: $0.0050 to $0.0199
• Volume: 29,945 shs
• Average Volume: 180,476 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNBX Pharmaceuticals Stock Analysis - MarketRank™

CNBX Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CNBX Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNBX Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNBX Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

CNBX Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNBX Pharmaceuticals has recently decreased by 87.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNBX Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNBX Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

CNBX Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNBX Pharmaceuticals has recently decreased by 87.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CNBX Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for CNBX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added CNBX Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNBX Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

73.51% of the stock of CNBX Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.18% of the stock of CNBX Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNBX Stock Analysis - Frequently Asked Questions

How have CNBX shares performed this year?

CNBX Pharmaceuticals' stock was trading at $0.0142 at the beginning of 2024. Since then, CNBX shares have decreased by 54.9% and is now trading at $0.0064.
View the best growth stocks for 2024 here.

When did CNBX Pharmaceuticals' stock split?

Shares of CNBX Pharmaceuticals reverse split on the morning of Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Cannabis Science (CBIS), KushCo (KSHB) and Trulieve Cannabis (TCNNF).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:CNBX
• CUSIP: N/A
• CIK: 1343009
• Web: www.cannabics.com
• Phone: (877) 424-2429
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A